Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialHelen M. Colhoun, John Fuller, D. J. Betteridge et al.|The Lancet|2004Cited by 3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Željko Reiner, Alberico L. Catapano, Guy De Backer et al.|European Heart Journal|2011Cited by 3.5k
Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With StatinsS. Matthijs Boekholdt, John J.P. Kastelein, Benoît J. Arsenault et al.|JAMA|2012Cited by 800
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trialsJane Armitage, Martin Landray, Michael Clearfield et al.|The Lancet|2019Cited by 785
Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)Helen M. Colhoun, John Fuller, D. J. Betteridge et al.|American Journal of Kidney Diseases|2009Cited by 253